Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim Day +3 vs Day +1 in Lymphoma Salvage Chemotherapy
NCT02238873Phase 3Unknown
- Sponsor
- Rabin Medical Center
- Start
- Oct 2014
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pegfilgrastim in neutropenia (2 arms), sponsored by Rabin Medical Center. Primary endpoints: Febrile neutropenia at 30 days and Neutrophil count <500/mcL. Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02238873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238873.